title: Customized targeted therapy in Hodgkin lymphoma: hype or hope?
abstract: Although most patients with Hodgkin lymphoma (HL) are cured with primary therapy, patients with primary refractory disease or relapse after initial treatment have poor outcomes and represent an unmet medical need. Recent advances in unraveling the biology of HL have yielded a plethora of novel targeted therapies. This review provides an overview of the data behind the hype generated by these advances and addresses the question of whether or not clinically these targeted therapies offer hope for patients with HL.
authors.affiliation: Department of Medicine, New York University School of Medicine/New York University Cancer Center, 240 East 38th Street, New York, NY 10016, USA.
authors.forename: Catherine
authors.initials: C
authors.lastname: Diefenbach
authors.forename: Ranjana
authors.initials: R
authors.lastname: Advani
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors; D058990:Molecular Targeted Therapy; D015398:Signal Transduction / Q000187:drug effects; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D017730:Ki-1 Antigen
keywords: Brentuximab vedotin; Hodgkin lymphoma; Relapsed disease; Targeted therapies